Last reviewed · How we verify

Standard Clinical Practice Regimen — Competitive Intelligence Brief

Standard Clinical Practice Regimen (Standard Clinical Practice Regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI. Area: Psychiatry.

marketed SSRI SERT, NET Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Standard Clinical Practice Regimen (Standard Clinical Practice Regimen) — Health Research, Inc.. This drug works by inhibiting the reuptake of serotonin and norepinephrine in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Standard Clinical Practice Regimen TARGET Standard Clinical Practice Regimen Health Research, Inc. marketed SSRI SERT, NET
tramadol HCl ER; celecoxib tramadol HCl ER; celecoxib Bausch Health Americas, Inc. phase 3 Opioid analgesic + selective COX-2 inhibitor (NSAID) Opioid receptors (μ, δ, κ); monoamine transporters (SERT, NET); COX-2
ketamine venlafaxine ketamine venlafaxine University Hospital, Grenoble phase 3 NMDA receptor antagonist, SNRI NMDA receptor, SERT, NET
Trintellix vortioxetine Takeda marketed Serotonin modulator and stimulator (SMS); SSRI-like agent Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor 2013-01-01
Lexapro escitalopram Generic (originally Lundbeck/Forest) marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin (5-HT) reuptake transporter 2002-08-14
Zoloft sertraline Pfizer Inc. marketed SSRI (Selective serotonin reuptake inhibitor) Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A 1991-12-30
Prozac fluoxetine Eli Lilly and Company marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin reuptake transporter 1987-12-29

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI class)

  1. Washington University School of Medicine · 2 drugs in this class
  2. Astellas Pharma Inc · 1 drug in this class
  3. Beni-Suef University · 1 drug in this class
  4. Bristol-Myers Squibb · 1 drug in this class
  5. Centre of Clinical Pharmacology, Hanoi Medical University · 1 drug in this class
  6. Chonbuk National University Hospital · 1 drug in this class
  7. EMS · 1 drug in this class
  8. Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 1 drug in this class
  9. PMG Pharm Co., Ltd · 1 drug in this class
  10. PT Bio Farma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard Clinical Practice Regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-clinical-practice-regimen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: